SubsidieMeestersSystemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.
Projectdetails
Introduction
Solid tumors, in particular metastatic ones, represent unmet clinical needs and are the second leading cause of death worldwide. Oncolytic viruses (OVs) kill tumors and spare normal cells. They are a distinct class of novel anti-cancer agents, frequently administered by intratumoral injection.
Systemic Delivery of OVs
A Holy Grail in the innovation of OVs is the possibility to administer them systemically, e.g., through intravenous injection, so that in the human body, OVs can search for and scavenge metastases. The systemic delivery of OVs addresses societal challenges as it meets the needs of metastatic patients, who are those that die of cancer and require innovative therapies the most.
Innovative Oncolytic Herpesviruses
The Principal Investigator has generated a family of innovative oncolytic herpesviruses (ReHVs) that specifically target HER2-positive tumors (HER2-ReHVs). In preclinical studies, HER2-ReHVs exhibit:
- High specificity for HER2-positive cancers
- High anti-tumor efficacy against metastatic tumors
- Vaccination against metastatic-like tumors
- High safety profile
These properties position ReHVs for systemic delivery. The ReHV technology is protected by a portfolio of patents.
Objectives of the Proposal
The objectives of this Proposal are twofold:
- To improve the systemic delivery of ReHVs by identifying the obstacles that constrain such administration, and to develop novel strategies to overcome them, including high-risk high-gain modifications that make ReHVs better suited for systemic delivery.
- To carry out initiatives for technological transfer, i.e., the development and commercialization of ReHVs. This includes the detailed planning of activities to take ReHVs to the authorization for First-in-Human clinical experimentation, developing a business plan, conducting OV market analysis, and searching for investors.
Conclusion
By combining the development and commercialization initiatives with technological advancements, this POC is expected to achieve the broader objective of progressing ReHVs into clinical experimentation and ultimately bringing them to patients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-5-2022 |
| Einddatum | 31-10-2023 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FONDAZIONE POLICLINICO SANT'ORSOLA ONLUSpenvoerder
- ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Macrophage-based immunotherapy of platinum-resistant ovarian cancerThe MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies. | EIC Transition | € 2.499.998 | 2022 | Details |
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicideThis project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma. | ERC COG | € 1.992.235 | 2024 | Details |
IntraVenous Immune BoostHEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Targeting the undruggable: Leveraging neomorphic DNA-binding preferences of chimeric fusion oncogenes to promote cancer suicide
This project aims to develop a novel viral vector strategy that leverages oncogenic transcription factors to selectively induce cancer cell suicide in aggressive tumors like Ewing sarcoma.
IntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.